Ulcers and gastritis

Endoscopy

Volumn 40, Issue 2, 2008, Pages 136-139

  Pang, S H ^a   Leung, W K ^a   Graham, D Y ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTITHROMBOCYTIC AGENT; CELECOXIB; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; NAPROXEN; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPSINOGEN; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; STOMACH SECRETION INHIBITOR; TINIDAZOLE; VALDECOXIB;

ANTIBIOTIC RESISTANCE; ARTICLE; CANCER SCREENING; CANCER STAGING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; ERADICATION THERAPY; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROSCOPY; HEART INFARCTION; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; STOMACH BIOPSY; STOMACH CANCER; STOMACH PROTECTION;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; FEMALE; GASTRIC MUCOSA; GASTRITIS; GASTROSCOPY; HELICOBACTER INFECTIONS; HUMANS; MALE; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PROGNOSIS; RISK ASSESSMENT; STOMACH NEOPLASMS;

EID: 39749172491     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995318     Document Type: Article

References (21)

1. Lanas A, Garcia-Rodriguez LA, Arroyo MT et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with non-steroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102: 507-515
2. Chan FK, Wong VW, Suen BY et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomized trial. Lancet 2007; 369: 1621-1626
3. Abraham NS, El-Serag HB, Hartman C et al. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007; 25: 913-924
4. Take S, Mizuno M, Ishiki K et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol 2007; 42: 21-27
5. Vaira D, Zullo A, Vakil N et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-563
6. Chan FK, Hung LC, Suen BY et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104-2110
7. Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-973
8. Lai KC, Chu KM, Hui WM et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005; 118: 1271-1278
9. Hoer A, Gothe H, Schiffhorst G et al. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalization due to peptic ulcer disease. Pharmacoepidemiol Drug Saf 2007; 16: 854-858
10. Garcia-Rodriguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007; 132: 498-506
11. Lanas A, Garcia-Rodriguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-1738
12. Bombardier C, Laine L, Recin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000: 343: 1520-1528
13. Solomon DH, Avorn J, Sturmer T et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006; 54: 1378-1389
14. Fries S, Grosser T, Price TS et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006; 130: 55-64
15. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789
16. Rugge M, Meggio A, Pennelli G et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56: 631-636
17. Watabe H, Mitsushima T, Yamaji Y et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54: 764-768
18. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 3: 87-97
19. Nagahara A, Miwa H, Ogawa K et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000; 5: 88-93
20. Treiber G, Ammon S, Schneider E et al. Amoxicillin/metronidazole/ omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998; 3: 54-58
21. Sugimoto M, Furuta T, Shirai N et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12: 317-323